Immatics

+$0.11 (+1.03%) As of 1:25 PM UTC pre-market

Why Robinhood?

You can buy or sell Immatics and other stocks, options, and ETFs commission-free!

About IMTX

Immatics N.V. Ordinary Shares, also called Immatics, is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer.

CEO
Harpreet Singh-Jasuja
Employees
198
Headquarters
Tuebingen, Baden Wuerttemberg
Founded
2000

IMTX Key Statistics

Market Cap
692.48M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
199.01K
High Today
$10.80
Low Today
$10.53
Open Price
$10.53
Volume
191.16K
52 Week High
$18.42
52 Week Low
$8.67

IMTX Earnings

-$0.54
-$0.36
-$0.18
$0.00
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected Jun 1, Pre-Market

You May Also Like

SBI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure